Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety
Anxiety
Primary: Pediatric Anxiety Rating Scale at Posttreatment — 7.21; 7.73 units on a scale
Phase 4 N=100 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery
Oxidative Stress · Cognition Disorders
Primary: Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) — 12; 8 Participants — p=0.289
Phase 4 N=54 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Insulin Resistance — 1.9997; 2.5824 HOMA-IR scores
N/A N=32 The Back Exercises to Neutralize Disability Study
Low Back Pain
Primary: Trunk Extensor Muscle Cross Sectional Area % of Change — -1.7; -3.9 percentage of change
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
N/A N=159 Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA
Total Knee Arthroplasty · Osteoarthritis · Post Operative Pain Control
Primary: Patients With Severe Pain at 48 Hours After Surgery — 21; 14; 12 percentage of patients with severe pain
N/A N=20 Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction & Laxity of the Flanks
Adipose Tissue
Primary: General Improvement in Skin Laxity of the Flank Area — 1.1; 2.1 units on a scale — p=<0.01
N/A N=398 Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation (PAF)
Primary: Procedure-related Complication Free Rate — 140; 148 Participants
Phase 4 N=23 Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))
Healthy · Attention Deficit Hyperactivity Disorder
Primary: Reaction Time Variability on the Multi-Source Interference Task — .22; .23; .26; .20 seconds — p=.02
Phase 2 N=158 A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
Influenza
Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants
Phase 2 N=112 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 3 N=225 Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Meningococcal Disease · Infections, Meningococcal
Primary: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA) Titer ≥ 1:5 Against Neisseria Meningitidis Serogroup B Strains — 0; 0; 100; 0 Percentages of subjects
Phase 2 N=71 KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Adult T-cell Leukemia-Lymphoma
Primary: Overall Response Rate — 2; 0; 0; 0 participants